Earnings Reports for Feb. 1

The 540,000 lines in service at the end of the year represent a rise of more than 500 percent over the number in service at the end of 1999, it said. BACK TO TOP UPS' global volume — a key measure of financial health in the package delivery industry — averaged 14.7 million pieces a day in the quarter, up 3.6 percent from the same period last year.

UPS averaged volume of about 1.3 million pieces a day for its entire international service, a 13.3 percent gain from last year. Volumes for the company's U.S. domestic package business averaged about 13.5 million pieces a day, a 2.8 percent rise over the year-earlier period.

UPS, which was recently awarded a new China route, said it "remained bullish" on its international markets. BACK TO TOP

Schering-Plough Reports Healthy Earnings

Drug maker Schering-Plough said today that fourth-quarter profits rose 13 percent, in line with estimates, on strong sales of its allergy drug Claritin and its Rebetron therapy for Hepatitis C.

The Kenilworth, N.J.-headquartered firm said it earned $571 million, or 39 cents per share in the quarter, compared with $506 million, or 34 cents per share, in the year-ago period.

Schering-Plough was expected to earn 39 cents a share during the quarter, said First Call/Thomson Financial, which compiles securities analysts' profit expectations.

Fourth-quarter sales rose 6 percent to $2.4 billion from $2.3 billion a year ago.

U.S. pharmaceutical sales rose 11 percent to $1.3 billion.

The company said Claritin sales rose 15 percent in the quarter to $662 million, while Rebetron sales grew 9 percent to $324 million.

Global fourth-quarter sales of the company's nasal-inhaled asthma drugs, led by Nasonex, jumped 12 percent to $151 million. Its anti-clotting drug Integrilin saw sales of $50 million, up from $20 million in the 1999 quarter.

Sales of Remicade for rheumatoid arthritis and Crohn's Disease were $21 million in the quarter, compared with $6 million in the year-ago period.

Page
Join the Discussion
blog comments powered by Disqus
 
You Might Also Like...